Peculiarities of changes in anticoagulant and coagulant activity in patients with coronary artery disease combined with type 2 diabetes mellitus
Background. Determining the features of regulatory mechanisms of plasma hemostasis in patients with coronary artery disease (CAD) and concomitant type 2 diabetes mellitus (DM) is of theoretical and practical interest, as it gives an opportunity, on the one hand, to establish their correlation with clinical manifestations and, thus, to predict the occurrence and development of complications, and on the other — to work out the additional diagnostic, curative, preventive approaches to the management of these patients. The purpose of the work is to study and analyze the state of anticoagulant and coagulant activity in patients with CAD and CAD with concomitant type 2 DM. Materials and methods. During the study of the anticoagulant and coagulant system, 50 patients were hospitalized in the cardiology and endocrinology department of the Kyiv Railway Clinical Hospital No. 2 with clinical signs of coronary artery disease. We selected 25 patients with CAD, and 25 — with CAD and type 2 DM. Results. We found that the comorbidity of CAD and type 2 diabetes mellitus is characterized by activation of all blood coagulation units, with a predominant activation of the final stage — the formation of a blood clot, as evidenced by statistically significant shortening of prothrombin time by 17.6 % (p < 0.001), and an increase in fibrinogen level by 39.6 % (p < 0.001) compared to the control group. In this group of patients, there was a significant decrease in the anticoagulant potential. Hypercoagulation shifts in the hemostasis system occurred against the background of inhibition of its own anticoagulant blood potential. The changes of coagulant potential in case of combination with type 2 DM were characterized by the acceleration of coagulation processes in all three stages of coagulation (prothrombinase, thrombin and fibrin formation). Conclusions. Data have shown that in patients with coronary artery disease without comorbidity and in people with coronary artery disease combined with type 2 diabetes mellitus, there is an inhibition of anticoagulant activity and an increase in the coagulant potential of the blood, which, in turn, increases the risk of vascular diseases.
Full Text:PDF (Українська)
Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016 Jan 14;37(3):267-315. doi: 10.1093/eurheartj/ehv320.
Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012 Oct;33(20):2569-619. doi: 10.1093/eurheartj/ehs215.
Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016 Sep 6;68(10):1082-115. doi: 10.1016/j.jacc.2016.03.513.
Bhatt DL, Eagle KA, Ohman EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010 Sep 22;304(12):1350-7. doi: 10.1001/jama.2010.1322.
Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J. 2015 May 14;36(19):1163-70. doi: 10.1093/eurheartj/ehu505.
Scirica BM, Bonaca MP, Braunwald E, et al. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial. Lancet. 2012 Oct 13;380(9850):1317-24. doi: 10.1016/S0140-6736(12)61269-0.
Mauri L, Kereiakes DJ, Yeh RW, et al; DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014 Dec 4;371(23):2155-66. doi: 10.1056/NEJMoa1409312.
Antonucci E, Poli D, Tosetto A, et al; START-Register. The Italian START-Register on Anticoagulation with Focus on Atrial Fibrillation. PLoS One. 2015 May 22;10(5):e0124719. doi: 10.1371/journal.pone.0124719.
Bohula EA, Bonaca MP, Braunwald E, et al. Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction. Circulation. 2016 Jul 26;134(4):304-13. doi: 10.1161/CIRCULATIONAHA.115.019861.
Costa F, van Klaveren D, James S, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet. 2017 Mar 11;389(10073):1025-1034. doi: 10.1016/S0140-6736(17)30397-5.
Stefanescu Schmidt AC, Kereiakes DJ, Cutlip DE, et al; DAPT Investigators. Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy). Circulation. 2017 May 2;135(18):1720-1732. doi: 10.1161/CIRCULATIONAHA.116.024835.
Patti G, Cavallari I. Extended duration dual antiplatelet therapy in patients with myocardial infarction: A study-level meta-analysis of controlled randomized trials. Am Heart J. 2016 Jun;176:36-43. doi: 10.1016/j.ahj.2016.03.005.
Secemsky EA, Yeh RW, Kereiakes DJ, et al; Dual Antiplatelet Therapy Study Investigators. Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study. JACC Cardiovasc Interv. 2017 May 8;10(9):942-954. doi: 10.1016/j.jcin.2017.02.013.
Bonaca MP, Bhatt DL, Storey RF, et al. Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. J Am Coll Cardiol. 2016 Jun 14;67(23):2719-2728. doi: 10.1016/j.jacc.2016.03.524.
Mangiacapra F, Peace A, Barbato E, et al. Thresholds for platelet reactivity to predict clinical events after coronary intervention are different in patients with and without diabetes mellitus. Platelets. 2014;25(5):348-56. doi: 10.3109/09537104.2013.824562.
Meredith IT, Tanguay JF, Kereiakes DJ, et al; DAPT Study Investigators. Diabetes Mellitus and Prevention of Late Myocardial Infarction After Coronary Stenting in the Randomized Dual Antiplatelet Therapy Study. Circulation. 2016 May 3;133(18):1772-82. doi: 10.1161/CIRCULATIONAHA.115.016783.
Bhatt DL, Bonaca MP, Bansilal S, et al. Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54. J Am Coll Cardiol. 2016 Jun 14;67(23):2732-2740. doi: 10.1016/j.jacc.2016.03.529.
This work is licensed under a Creative Commons Attribution 4.0 International License.
© "Publishing House "Zaslavsky", 1997-2019